Expert opinion in biological therapy: Update on developments in lung gene transfer

Expert Opinion on Biological Therapy

Volumn 13, Issue 3, 2013, Pages 345-360

  Griesenbach, Uta ^b   Alton, Eric W F W ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Acute lung injury; Airways; Alpha 1 antitrypsin deficiency; Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Gene therapy; Lung infection; Lung transplantation; Non viral gene transfer agents; Primary ciliary dyskinesia; Surfactant protein B deficiency; Viral gene transfer agents

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOVIRUS VECTOR; AIR 645; AL RSV 01; ALN RSV 01; ALPHA 1 ANTITRYPSIN; ANGIOPOIETIN 1; ANTISENSE OLIGONUCLEOTIDE; AXONEMAL DYNEIN; CPG OLIGODEOXYNUCLEOTIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DYNEIN AXONEMAL INTERMEDIATE CHAIN TYPE 1; INTERLEUKIN 10; KERATINOCYTE GROWTH FACTOR; LENTIVIRUS VECTOR; LIPOPLEX; LUCIFERASE; PARVOVIRUS VECTOR; PGM 169; PLASMID DNA; POLYETHYLENEIMINE; RETROVIRUS VECTOR; SURFACTANT PROTEIN B; TPI ASM 8; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALPHA ANTITRYPSIN DEFICIENCY; ASTHMA; BIOLOGICAL THERAPY; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY DYSKINESIA; CPG ISLAND; CYSTIC FIBROSIS; DNA METHYLATION; DRUG DOSE ESCALATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; LUNG GRAFT REJECTION; LUNG INFECTION; LUNG TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PROTEIN DEFICIENCY; REPORTER GENE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RNA INTERFERENCE; SCALE UP; SINGLE DRUG DOSE; SURFACTANT B DEFICIENCY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

BIOLOGICAL THERAPY; EXPERT TESTIMONY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LUNG DISEASES;

EID: 84873888481     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.735656     Document Type: Review

References (124)

1. American Society of Cell and Gene Therapy. 2000
2. Breeze RG, Wheeldon EB. The cells of the pulmonary airways. Am Rev Respir Dis 1977;116:705-77
3. Griesenbach U, Alton EW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des 2012;18:642-62
4. Pickles RJ, McCarty D, Matsui H, et al. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol 1998;72:6014-23
5. Walters RW, Grunst T, Bergelson JM, et al. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem 1999;274:10219-26
6. Weiss DJ, Beckett T, Bonneau L, et al. Transient increase in lung epithelial tight junction permeability: an additional mechanism for enhancement of lung transgene expression by perfluorochemical liquids. Mol Ther 2003;8:927-35
7. Koehler DR, Frndova H, Leung K, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med 2005;7:1409-20
8. Flotte TR, Ng P, Dylla DE, et al. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 2007;15:229-41
9. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998;72:8568-77
10. Flotte TR. Recent developments in recombinant AAV-mediated gene therapy for lung diseases. Curr Gene Ther 2005;5:361-6
11. McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004;38:819-45
12. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005;5:285-97
13. Limberis MP, Vandenberghe LH, Zhang L, et al. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 2009;17:294-301
14. Flotte TR, Fischer AC, Goetzmann J, et al. Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther 2010;18:594-600
15. Bell CL, Vandenberghe LH, Bell P, et al. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 2011;121:2427-35
16. Maheshri N, Koerber JT, Kaspar BK, et al. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006;24:198-204
17. Excoffon KJ, Koerber JT, Dickey DD, et al. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci USA 2009;106:3865-70
18. Li W, Zhang L, Johnson JS, et al. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther 2009;17:2067-77
19. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 2001;4:383-91
20. Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol 2002;20:697-701
21. Song Y, Lou HH, Boyer JL, et al. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing. Hum Gene Ther 2009;20:267-81
22. Ferrari S, Griesenbach U, Shiraki-Iida T, et al. A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther 2004;11:1659-64
23. Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005;79:1113-24
24. Okada Y. Sendai virus-induced cell fusion. Methods Enzymol 1993;221:18-41
25. Li HO, Zhu YF, Asakawa M, et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000;74:6564-9
26. Inoue M, Tokusumi Y, Ban H, et al. Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J Virol 2003;77:3238-46
27. Kobayashi M, Iida A, Ueda Y, et al. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol 2003;77:2607-14
28. Mitomo K, Griesenbach U, Inoue M, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with sendai virus envelopes. Mol Ther 2010;18:1173-82
29. Sinn PL, Arias AC, Brogden KA, et al. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol 2008;82:10684-92
30. McKay T, Patel M, Pickles RJ, et al. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther 2006;13:715-24
31. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005;12:1089-98
32. Wilson AA, Murphy GJ, Hamakawa H, et al. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest 2010;120:379-89
33. Limberis M, Anson DS, Fuller M, et al. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002;13:1961-70
34. Cmielewski P, Anson DS, Parsons DW. Lysophosphatidylcholine as an adjuvant for lentiviral vector mediated gene transfer to airway epithelium: effect of acyl chain length. Respir Res 2010;11:84
35. Medina MF, Kobinger GP, Rux J, et al. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther 2003;8:777-89
36. Griesenbach U, Inoue M, Hasegawa M, et al. Viral vectors for cystic fibrosis gene therapy-what does the future hold? Virus Adaptat Treat 2010;2010:159-71
37. Griesenbach U, McLachlan G, Owaki T, et al. Validation of recombinant sendai virus in a non-natural host model. Gene Ther 2010;18:182-8
38. Booth C, Gaspar HB, Thrasher AJ. Gene therapy for primary immunodeficiency. Curr Opin Pediatr 2011;23:659-66
39. Mukherjee S, Thrasher AJ. Progress and prospects: advancements in retroviral vector design, generation, and application. Hum Gene Ther 2011;22:1171-4
40. Pichon C, Billiet L, Midoux P. Chemical vectors for gene delivery: uptake and intracellular trafficking. Curr Opin Biotechnol 2010;21:640-5
41. Hyde SC, Southern KW, Gileadi U, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000;7:1156-65
42. Ziady AG, Kelley TJ, Milliken E, et al. Functional evidence of CFTR gene transfer in nasal epithelium of cystic fibrosis mice in vivo following luminal application of DNA complexes targeted to the serpin-enzyme complex receptor. Mol Ther 2002;5:413-19
43. Tagalakis AD, McAnulty RJ, Devaney J, et al. A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer. Mol Ther 2008;16:907-15
44. Davies LA, McLachlan G, Sumner-Jones SG, et al. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther 2008;16:1283-90
45. Davies LA, Hyde SC, Nunez-Alonso G, et al. The use of CpG-free plasmids to mediate persistent gene expression following repeated aerosol delivery of pDNA/PEI complexes. Biomaterials 2012;33:5618-27
46. Pfeifer C, Hasenpusch G, Uezguen S, et al. Dry powder aerosols of polyethylenimine (PEI)-based gene vectors mediate efficient gene delivery to the lung. J Control Release 2011;154:69-76
47. Gazdhar A, Fachinger P, van LC, et al. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007;292:L529-36
48. Mutlu GM, Hado-Aranda D, Norton JE, et al. Electroporation-mediated gene transfer of the Na+, K+-ATPase rescues endotoxin-induced lung injury. Am J Respir Crit Care Med 2007;176:582-90
49. Pringle IA, McLachlan G, Collie DD, et al. Electroporation enhances reporter gene expression following delivery of naked plasmid DNA to the lung. J Gene Med 2007;9:369-80
50. Kaufman CD, Geiger RC, Dean DA. Electroporation-and mechanical ventilation-mediated gene transfer to the lung. Gene Ther 2010;17:1098-104
51. Xenariou S, Griesenbach U, Ferrari S, et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006;13:1545-52
52. Xenariou S, Griesenbach U, Liang HD, et al. Use of ultrasound to enhance nonviral lung gene transfer in vivo. Gene Ther 2007;14:768-74
53. Griesenbach U, Meng C, Farley R, et al. The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways. Biomaterials 2010;31:2665-72
54. Griesenbach U, Meng C, Farley R, et al. The role of doxorubicin in non-viral gene transfer in the lung. Biomaterials 2009;30:1971-7
55. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008;26:549-51
56. Alton EW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999;353:947-54
57. Pringle IA, Raman S, Sharp WW, et al. Detection of plasmid DNA vectors following gene transfer to the murine airways. Gene Ther 2005;12:1206-14
58. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204
59. Qin L, Ding Y, Pahud DR, et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997;8:2019-29
60. Gill DR, Smyth SE, Goddard CA, et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Ther 2001;8:1539-46
61. Yew NS, Przybylska M, Ziegler RJ, et al. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 2001;4:75-82
62. Degiulio JV, Kaufman CD, Dean DA. The SP-C promoter facilitates alveolar type II epithelial cell-specific plasmid nuclear import and gene expression. Gene Ther 2010;17:541-9
63. Bazzani RP, Cai Y, Hebel HL, et al. The significance of plasmid DNA preparations contaminated with bacterial genomic DNA on inflammatory responses following delivery of lipoplexes to the murine lung. Biomaterials 2011;32:9854-65
64. Munkonge FM, Amin V, Hyde SC, et al. Identification and functional characterization of cytoplasmic determinants of plasmid DNA nuclear import. J Biol Chem 2009;284:26978-87
65. Chen ZY, He CY, Ehrhardt A, et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003;8:495-500
66. Sinn PL, Shah AJ, Donovan MD, et al. Viscoelastic gel formulations enhance airway epithelial gene transfer with viral vectors. Am J Respir Cell Mol Biol 2005;32:404-10
67. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6:1574-83
68. Mudhakir D, Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J 2009;11:65-77
69. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther 2010;17:439-47
70. Ding W, Zhang L, Yan Z, et al. Intracellular trafficking of adeno-associated viral vectors. Gene Ther 2005;12:873-80
71. Lee K, Ambrose Z, Martin TD, et al. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 2010;7:221-33
72. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 2011;6:147-63
73. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-93
74. Devaney J, Contreras M, Laffey JG. Clinical review: gene-based therapies for ALI/ARDS: where are we now? Crit Care 2011;15:224
75. Machado-Aranda DA, Suresh MV, Yu B, et al. Electroporation-mediated in vivo gene delivery of the Na+/K+-ATPase pump reduced lung injury in a mouse model of lung contusion. J Trauma Acute Care Surg 2012;72:32-9
76. Kabay B, Kocaefe C, Baykal A, et al. Interleukin-10 gene transfer: prevention of multiple organ injury in a murine cecal ligation and puncture model of sepsis. World J Surg 2007;31:105-15
77. Ulrich K, Stern M, Goddard ME, et al. Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005;288:L1179-92
78. Huang YQ, Sauthoff H, Herscovici P, et al. Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury. Crit Care Med 2008;36:262-7
79. Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007;4:e269
80. Manning E, Pham S, Li S, et al. Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemia-reperfusion injury. Hum Gene Ther 2010;21:713-27
81. Aguilar S, Scotton CJ, McNulty K, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009;4:e8013
82. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360:2749-57
83. Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 2000;11:1023-32
84. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006;17:1177-86
85. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 2009;106:16363-8
86. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2011;22:1239-47
87. Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88:891-7
88. Halbert CL, Madtes DK, Vaughan AE, et al. Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther 2010;18:1165-72
89. Griesenbach U, Vicente CC, Roberts MJ, et al. Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer. Biomaterials 2011;32:2614-24
90. Maes T, Tournoy KG, Joos GF. Gene therapy for allergic airway diseases. Curr Allergy Asthma Rep 2011;11:163-72
91. Gauvreau GM, Boulet LP, Cockcroft DW, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008;177:952-8
92. Gauvreau GM, Pageau R, Seguin R, et al. Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy 2011;66:1242-8
93. Imaoka H, Campbell H, Babirad I, et al. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin Exp Allergy 2011;41:1740-6
94. Webb S. Attacks on asthma. Nat Biotechnol 2011;29:860-3
95. Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 2008;8:300-7
96. Al-Jamal R, Wallace WA, Harrison DJ. Gene therapy for chronic obstructive pulmonary disease: twilight or triumph? Expert Opin Biol Ther 2005;5:333-46
97. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73
98. Quinton PM. Role of epithelial HCO3 transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol 2010;299:C1222-33
99. Welsh M, Ramsey BW, Accurso F, et al. Cystic fibrosis. In: Scriver AB, Sly WS, Valle D. The molecular and metabolic basis of inherited disease. McGraw-Hill; New York: 2001. p. 5121-88
100. Clunes MT, Boucher RC. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discov Today Dis Mech 2007;4:63-72
101. Alton EW, Middleton PG, Caplen NJ, et al. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet 1993;5:135-42
102. Drumm ML, Pope HA, Cliff WH, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990;62:1227-33
103. Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993;3:151-6
104. Johnson LG, Olsen JC, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-5
105. Farmen SL, Karp PH, Ng P, et al. Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl-transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005;289:L1123-30
106. Johnson LG, Boyles SE, Wilson J, et al. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995;95:1377-82
107. Harvey BG, Leopold PL, Hackett NR, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999;104:1245-55
108. Devincenzo JP. The promise, pitfalls and progress of RNA-interference- based antiviral therapy for respiratory viruses. Antivir Ther 2012;17:213-25
109. Alvarez R, Elbashir S, Borland T, et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009;53:3952-62
110. Devincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008;77:225-31
111. Devincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010;107:8800-5
112. Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011;183:531-8
113. Oishi H, Okada Y, Kikuchi T, et al. Transbronchial human interleukin-10 gene transfer reduces acute inflammation associated with allograft rejection and intragraft interleukin-2 and tumor necrosis factor-alpha gene expression in a rat model of lung transplantation. J Heart Lung Transplant 2010;29:360-7
114. Hirayama S, Sato M, Liu M, et al. Local long-term expression of lentivirally delivered IL-10 in the lung attenuates obliteration of intrapulmonary allograft airways. Hum Gene Ther 2011;22:1453-60
115. Jiang X, Khan MA, Tian W, et al. Adenovirus-mediated HIF-1alpha gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest 2011;121:2336-49
116. Cypel M, Keshavjee S. Extracorporeal lung perfusion. Curr Opin Organ Transplant 2011;16:469-75
117. Yeung JC, Wagnetz D, Cypel M, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre-and post-lung transplantation in the pig. Mol Ther 2012;20:1204-11
118. Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009;1:4ra9
119. Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol 2009;12:253-74
120. Yei S, Bachurski CJ, Weaver TE, et al. Adenoviral-mediated gene transfer of human surfactant protein B to respiratory epithelial cells. Am J Respir Cell Mol Biol 1994;11:329-36
121. Kormann MS, Hasenpusch G, Aneja MK, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011;29:154-7
122. Chhin B, Negre D, Merrot O, et al. Ciliary beating recovery in deficient human airway epithelial cells after lentivirus ex vivo gene therapy. PLoS Genet 2009;5:e1000422
123. Stillwell PC, Wartchow EP, Sagel SD. Primary ciliary dyskinesia in children: a review for pediatricians, allergists, and pediatric pulmonologists. Pediatr Allergy Immunol Pulmonol 2011;24:191-6
124. The authors are strategy members of the UK Cystic Fibrosis Gene Therapy Consortium. Available from: http://www. cfgenetherapy.org.uk